Volume 19, Number 6—June 2013
Dispatch
Human Melioidosis, Malawi, 2011
Table 2
Year (reference) | Country where acquired (diagnosed) | Details of infected persons | Clinical characteristics | Diagnostic method (source of isolation) | Definitive treatment (duration, wk) | Outcome |
---|---|---|---|---|---|---|
1982 (10) | Kenya (Denmark) | Adult | Sepsis | Culture (blood, urine, sputum) | OTC (4); cotrimoxazole TMP-SXT (8) | Complete recovery |
1985 (11) | Sierra Leone (Gambia) | Child | Cutaneous abscesses, osteomyelitis | Culture; indirect hemagglutination (pus) | CHL, TET | Improved; lost to follow up |
2004 (12) |
Mauritius (Mauritius) |
Adult with SLE |
Sepsis, cellulitis |
Culture; API 2ONE (blood) |
None |
Died (d 9) |
2004 (13) | Madagascar (La Réunion) | Adult smoker, alcoholic | Sepsis, respiratory distress | Culture (blood, BAL fluid) | CAZ | Complete recovery |
Adult with CPI | Septicemia | Culture (blood, BAL fluid) | CAZ; cotrimoxazole (20) | Not described | ||
Adult with SLE |
Septicemia |
Culture (blood, BAL fluid) |
CAZ; cotrimoxazole (20) |
Not described |
||
2006 (14) | Madagascar (La Réunion) | Adult smoker | Pneumonia | Culture; API 20NE; PCR (BAL fluid); | IPM (2); cotrimoxazole (20) | Resolution at 3 mo |
2010 (15) | Africa† (France) | Adult | Mycotic aneurysm | Culture (blood, arterial tissue) | IPM + CIP (5); cotrimoxazole (20) | Resolution at 6 mo |
2011 (16) | Gambia (Spain) | Adult with diabetes mellitus | Pyomyositis, pneumonia | Culture; PCR (pus, sputum) | CAZ + cotrimoxazole (5); DOX + cotrimoxazole (20) | Complete recovery |
2011 (17) | Nigeria (UK) | Adult with diabetes mellitus | Localized lymphadenopathy | Culture; chromatography; PCR (blood) | Meropenem (1); cotrimoxazole (12) | Lost to follow-up |
2011 (18) | Africa† (Spain) | Adult | Sepsis | Culture (blood) | CAZ + DOX | Not described |
*OTC, oxytetracycline; TMP-SXT, trimethoprim–sulfamethoxazole; CHL, chloramphenicol; TET, tetracycline; SLE, systemic lupus erythematosus; BAL, bronchoalveolar lavage; CAZ, ceftazidime; CPI, chronic pulmonary insufficiency; IPM, imipenem; CIP, ciprofloxacin; DOX, doxycycline; MER, meropenem.
†Exposure was in multiple countries on the continent or the specific country of acquisition was not detailed.
1These authors contributed equally to this article.
Page created: May 20, 2013
Page updated: May 20, 2013
Page reviewed: May 20, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.